Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

   Recruiting · Phase 2, Phase 3 · Breast Neoplasms

   NCT06926868 · E.r. Squibb & Sons, L.l.c. · 32 U.S. investigators

   $42,615research payments

2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

   Recruiting · Phase 3 · Alzheimer's Disease

   NCT07011745 · E.r. Squibb & Sons, L.l.c. · 11 U.S. investigators

   $42,609research payments

3. Triathlon Tritanium Cone Augments Outcomes Study

   Active, not recruiting · Not applicable · Arthroplasty

   NCT02521103 · Stryker Corporation · 7 U.S. investigators

   $42,543research payments

4. Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

   Active, not recruiting · Phase 2 · Stargardt's Disease

   NCT01736592 · Genzyme Corporation · 1 U.S. investigator

   $42,252research payments

5. AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

   Active, not recruiting · Not applicable · Aortic Aneurysm, Abdominal

   NCT06029660 · Shape Memory Medical Inc. · 3 U.S. investigators

   $41,888research payments

6. Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

   Completed · Phase 1, Phase 2 · Chronic Graft Versus Host Disease

   NCT03790332 · AbbVie Inc. · 5 U.S. investigators

   $41,884research payments

7. Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

   Completed · Phase 2 · Lyme Borreliosis

   NCT03970733 · Valneva Austria GmbH · 3 U.S. investigators

   $41,879research payments

8. Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

   Completed · Phase 2 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy

   NCT04658472 · Sanofi US Services Inc. · 4 U.S. investigators

   $41,812research payments

9. A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

   Completed · Phase 4 · Type 2 Diabetes

   NCT05564039 · Eli Lilly and Company · 6 U.S. investigators

   $41,779research payments

10. The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial

    Recruiting · Non-cardiac Surgical

    NCT06895590 · Philips North America LLC · 2 U.S. investigators

    $41,250research payments

11. Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

    Recruiting · Phase 1 · Advanced Prostate Cancer

    NCT06062745 · Blue Earth Diagnostics · 1 U.S. investigator

    $40,526research payments

12. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

    Active, not recruiting · Phase 3 · Obesity

    NCT06972472 · Eli Lilly and Company · 30 U.S. investigators

    $40,397research payments

13. SPOTFIRE Sore Throat (ST) Study

    Completed · Not applicable · Pharyngitis, Infective

    NCT06713642 · Biomerieux Inc · 1 U.S. investigator

    $40,300research payments

14. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

    Active, not recruiting · Phase 2 · Acute Pyelonephritis

    NCT06672978 · Melinta Therapeutics, LLC · 5 U.S. investigators

    $40,201research payments

15. Efficacy & Safety of LOBO™ Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations

    Active, not recruiting · Not applicable · Pulmonary Arteriovenous Malformations

    NCT06735976 · Okami Medical, Inc. · 1 U.S. investigator

    $40,000research payments

16. Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America

    Recruiting · Dialysis

    NCT07262320 · Vantive US Healthcare LLC · 1 U.S. investigator

    $40,000research payments

17. Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

    Completed · Phase 4 · Generalized Lipodystrophy

    NCT04026178 · Chiesi USA, Inc. · 4 U.S. investigators

    $39,996research payments

18. A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

    Completed · Phase 3 · Endometriosis

    NCT03213457 · AbbVie Inc. · 9 U.S. investigators

    $39,751research payments

19. A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

    Completed · Phase 2 · Huntington Disease

    NCT05358717 · Ptc Therapeutics, Inc. · 5 U.S. investigators

    $39,687research payments

20. Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension

    Enrolling by invitation · Phase 4 · Vasodilatory Shock

    NCT07212686 · La Jolla Pharmaceutical Company · 1 U.S. investigator

    $39,370research payments

21. Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

    Terminated · Phase 2 · Rheumatoid Arthritis (RA)

    NCT04888585 · AbbVie Inc. · 4 U.S. investigators

    $39,280research payments

22. Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

    Terminated · Phase 3 · Adolescent Lupus Nephritis

    NCT05962788 · Aurinia Pharma U.S., Inc. · 2 U.S. investigators

    $39,150research payments

23. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

    Terminated · Phase 2 · Osteochondrodysplasia

    NCT06067425 · Genzyme Corporation · 1 U.S. investigator

    $38,880research payments

24. Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

    Active, not recruiting · Phase 1 · Advanced Malignancies

    NCT03233139 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $38,770research payments

25. Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

    Completed · Phase 1 · Diffuse Large B Cell Lymphoma

    NCT03028103 · Epizyme, Inc. · 1 U.S. investigator

    $38,489research payments

26. Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

    Recruiting · Phase 2 · Acute Myeloid Leukemia

    NCT06824168 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $38,467research payments

27. A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

    Completed · Phase 3 · Hepatocellular Carcinoma

    NCT02435433 · Eli Lilly and Company · 1 U.S. investigator

    $38,269research payments

28. Informed Choice - Compass

    Terminated · Colorectal Cancer

    NCT05246839 · Exact Sciences Corporation · 20 U.S. investigators

    $38,161research payments

29. Endoscopic Ultrasound Shear Wave Elastography Study

    Recruiting · MASLD

    NCT06592820 · Gyrus Acmi, Inc. · 3 U.S. investigators

    $37,895research payments

30. Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder Arthroplasty

    Active, not recruiting · Not applicable · Arthropathy of Shoulder Region

    NCT03726554 · Zimmer Biomet Holdings, Inc. · 2 U.S. investigators

    $37,870research payments

31. Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

    Active, not recruiting · Knee Pain Chronic

    NCT05787821 · Zimmer Biomet Holdings, Inc. · 2 U.S. investigators

    $37,768research payments

32. First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

    Completed · Phase 1 · Advanced Solid Tumors Cancer

    NCT04417465 · AbbVie Inc. · 5 U.S. investigators

    $37,542research payments

33. A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

    Recruiting · Alpha1-Antitrypsin Deficiency

    NCT06512454 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $37,333research payments

34. A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

    Withdrawn · Phase 1, Phase 2 · Phenylketonuria

    NCT06147856 · ModernaTX, Inc. · 5 U.S. investigators

    $37,294research payments

35. Secur-Fit Advanced Outcomes Study

    Terminated · Not applicable · Arthroplasty, Replacement, Hip

    NCT01917929 · Stryker Corporation · 5 U.S. investigators

    $36,997research payments

36. Dupilumab Skin Barrier Function Study in Atopic Dermatitis

    Completed · Phase 4 · Atopic Dermatitis

    NCT04447417 · Genzyme Corporation · 1 U.S. investigator

    $36,944research payments

37. Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

    Active, not recruiting · Phase 1 · Solid Tumors

    NCT03313778 · ModernaTX, Inc. · 2 U.S. investigators

    $36,827research payments

38. Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

    Completed · Phase 2 · Asthma

    NCT01312961 · Genzyme Corporation · 0 U.S. investigators

    $36,250research payments

39. A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

    Recruiting · Phase 1 · Psoriatic Arthritis

    NCT07290036 · UCB SA · 7 U.S. investigators

    $36,115research payments

40. Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

    Active, not recruiting · Not applicable · Prostate Cancer

    NCT04905069 · Boston Scientific Corporation · 5 U.S. investigators

    $35,993research payments

41. A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

    Recruiting · Phase 2 · Diabetic Peripheral Neuropathic Pain

    NCT07285018 · Eli Lilly and Company · 35 U.S. investigators

    $35,958research payments

42. International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

    Enrolling by invitation · Phase 2 · Plasma Cell Myeloma

    NCT05669989 · Sanofi US Services Inc. · 1 U.S. investigator

    $35,735research payments

43. Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

    Completed · Phase 1 · Mature B-cell Malignancies

    NCT04883957 · Beigene, Ltd. · 5 U.S. investigators

    $35,650research payments

44. Decision Impact Trial of KidneyIntelX

    Active, not recruiting · Diabetic Kidney Disease

    NCT04791358 · Renalytix Ai, Inc. · 6 U.S. investigators

    $35,020research payments

45. A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

    Recruiting · Phase 1 · Extensive-stage Small-cell Lung Cancer

    NCT06807632 · Daiichi Sankyo Inc. · 1 U.S. investigator

    $34,771research payments

46. Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

    Completed · Phase 3 · Pulmonary Emphysema in Alpha-1 PI Deficiency

    NCT01983241 · Grifols Therapeutics LLC · 3 U.S. investigators

    $34,434research payments

47. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    Recruiting · Phase 3 · Alzheimer Disease

    NCT06937229 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $34,269research payments

48. A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

    Recruiting · Phase 1, Phase 2 · Retinitis Pigmentosa

    NCT06891885 · Sumitomo Pharma America, Inc. · 2 U.S. investigators

    $34,222research payments

49. Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

    Recruiting · Liver Cancer

    NCT05517811 · Haemonetics Corporation · 1 U.S. investigator

    $34,200research payments

50. Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

    Recruiting · Amblyopia

    NCT06429280 · Luminopia, Inc. · 3 U.S. investigators

    $34,184research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.